Democratizing Genomics, Sequentify Raises $7M toEnable DNA Sequencing at Scale
Updated: Dec 29, 2022
600% revenue growth rate, Sequentify supplies Next Generation Sequencing libraries and software for cancer diagnostics, carrier screening and COVID-19 surveillance Sequentify will officially launch its InfiniSeq technology at Biomed Israel 2022
Rehovot, Israel - May 10, 2022 - Sequentify, a Weizmann Institute of Science spinoff, enables
fast and focused DNA sequencing. It combines tools from the synthetic biology and AI software
fields to enable rapid targeted DNA sequencing. Sequentify exits stealth mode with $7M in
raised funds led by Israel’s most active venture firm, OurCrowd. The funds will be used to
accelerate R&D, delivery, and go-to-market plans for the company.
Sequentify, on track to 600% revenue growth, already has multiple hospitals and labs as
customers, as well as over 70x valuation growth in less than 18 months.
OurCrowd CEO Jon Medved said, “We are excited to be leading this round because the DNA
revolution has just begun and Sequentify has the best next generation sequencing solution in
the market.”
Founded in 2021, Sequentify is based on a technology developed by Co-Founders Tamir
Biezuner and Tom Fleischer at the laboratory of Liran Shlush. Sequentify democratizes
genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI
software that enables fast, cost-effective, and automated sequencing. Sequentify’s NGS
products are based on its InfiniSeq proprietary platform and include COVID-19 surveillance,
cancer diagnostics, carrier screening and more.
Ophir Herbst, Co-Founder and CEO of Sequentify said, "With the decentralization of NGS into
local labs and hospitals and the expansion of NGS into clinical use, these institutions are in
need of easy-to-implement, fast and cost-effective NGS solutions. Sequentify enables DNA
screening at scale with the goal of making genomics as common and affordable as testing for
blood counts."
Sequentify will officially launch its InfiniSeq technology at Biomed Israel 2022 on May 11th. Sequentify’s CEO will participate in the “ACADEMIA - WHERE IS IT TAKING US? SCIENCE
AND TECHNOLOGY - PREDICTION AND ANTICIPATION” panel and it will exhibit at booth
#26.
Sequentify’s InfiniSeq technology condenses sample preparation lab time to only 3.5 hours from
DNA to sequencing, with one-tube reaction, full automation support, and dramatic cost
reduction. The patent-pending InfiniSeq technology adjusts to most sequencing instruments and
fits into any lab workflow, thus enabling full integration into laboratories that have so far
refrained from entering the sequencing field.
Herbst: ”As an Israeli company we are already collaborating with numerous sectors of the Israeli
healthcare community, including hospitals and medical service suppliers. Biomed, as the leading
event in the Israeli life sciences industry, is the natural venue to share Sequentify’s technology
and to form research and strategic collaborations.”
During the COVID-19 pandemic, Sequentify’s COVID-19 mutation surveillance kit enabled
mapping the entire COVID-19 viral genome in a cost-effective, fast and automated process
supporting the identification of existing and emerging variants such as Omicron and Delta.
Sequentify is also working on supporting liquid biopsy, epigenomics and virology across its
technologies.
About Sequentify:
Founded in 2021 as a Weizmann Institute of Science spinoff, Sequentify provides a technology
that is based on tools from the synthetic biology and AI software worlds for targeted DNA
sequencing applications such as cancer diagnostics, carrier screening, COVID-19 surveillance
and other applications. Sequentify is based in Rehovot, Israel. For more information, visit
Media Contact:
Avigayil Simpson
avigayil@sequentify.com